8-K: Salarius Pharmaceuticals Denies Nasdaq Delisting Claims

Salarius Pharmaceuticals, Inc. issued an 8-K filing to correct inaccurate reports of its delisting from the Nasdaq Capital Market, confirming its continued listing and trading.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) became aware on November 17, 2025, that certain financial market data platforms, including Yahoo Finance and CapIQ, published inaccurate information stating its delisting from the Nasdaq Capital Market effective November 13, 2025.
• The company explicitly states that this information is inaccurate and its common stock continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol SLRX.
• Salarius has contacted these platforms to correct the erroneous information.
• The company previously regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) on September 4, 2025.
• It also regained compliance with Nasdaq Listing Rule 5550(b)(1) (the Equity Standard) on October 10, 2025.
• On November 13, 2025, the company completed its strategic merger transaction with Decoy Therapeutics, Inc.
• Following the consummation of the merger, Salarius continues to be listed and traded on the Nasdaq Capital Market and has not received any notification from Nasdaq indicating non-compliance with continued listing requirements.

Sentiment

Score: 7

Explanation: The filing clarifies inaccurate delisting reports, confirming the company's continued Nasdaq listing and recent compliance achievements, including a strategic merger. While the need to correct misinformation is a slight negative, the underlying facts are positive for stability.

Positives

• The company confirmed it is not delisted and its common stock continues to trade on the Nasdaq Capital Market.
• Successfully regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) on September 4, 2025.
• Successfully regained compliance with Nasdaq's Equity Standard (Rule 5550(b)(1)) on October 10, 2025.
• Completed its strategic merger transaction with Decoy Therapeutics, Inc. on November 13, 2025.

Negatives

• Inaccurate delisting information was published by major financial market data platforms, potentially causing confusion or negative market reaction.

Future Outlook

The company is actively working to correct inaccurate delisting information on financial market data platforms and confirms its continued listing and trading on the Nasdaq Capital Market following the completion of its strategic merger with Decoy Therapeutics, Inc.

Management Comments

• The company confirmed that its common stock continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol SLRX, and it has not received any notification from Nasdaq indicating non-compliance with continued listing requirements.

Industry Context

The incident of inaccurate delisting reports underscores the challenges smaller biotechnology firms can face regarding market perception and data dissemination, especially after navigating compliance issues and executing strategic transactions like mergers, which are common for companies seeking to strengthen their position or pipeline.

Stakeholder Impact

• Shareholders: Reassurance that the company's stock is still listed and trading, potentially mitigating negative impact from inaccurate reports.
• Investors: Provides clarity and corrects misinformation, aiding informed investment decisions.
• Financial Data Platforms: Highlights the need for accuracy in data dissemination.

Next Steps

• Continue to work with financial market data platforms (e.g., Yahoo Finance, CapIQ) to correct inaccurate delisting information.
• Continue trading on the Nasdaq Capital Market under SLRX.

Key Dates

Recommendation

The filing primarily serves to correct inaccurate market information regarding the company's Nasdaq listing status. While the confirmation of continued listing and prior compliance with Nasdaq rules, along with the completed merger, are positive for stability and remove a significant overhang, the filing does not introduce new operational or financial catalysts that would warrant a 'buy' or 'sell' recommendation. Investors should hold their position while monitoring the integration of the Decoy Therapeutics merger and future operational updates.

Keywords

SLRX, Salarius Pharmaceuticals, Nasdaq, Delisting, Merger, Decoy Therapeutics, Compliance, Biotech, Pharmaceuticals